Search - tctmd.com

Displaying 961 - 980 of 1151

Sort: Relevancy | Date

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Conference News EHRA 2025

Post-TAVI Pacemaker Tied to Poorer Long-term Outcomes

Todd Neale

April 08, 2025

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

News Conference News EHRA 2025

Positive Results With Volt Pulsed-Field Ablation System

Todd Neale

April 07, 2025

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2025

Caitlin E. Cox

April 01, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

Presentation ACC 2025

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Presenter: William Fearon

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Features

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Yael L. Maxwell

March 27, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Advertisement

Cardiotoxicity Rare With Common GI Chemotherapy

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Post-TAVI Pacemaker Tied to Poorer Long-term Outcomes

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Positive Results With Volt Pulsed-Field Ablation System

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

TCTMD’s Top 10 Most Popular Stories for March 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

WARRIOR: No Clear Answers on How to Best Treat INOCA

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

What’s Going to Be Hot at ACC 2025?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content